Real-world costs of chronic lymphocytic leukaemia in the Netherlands

Leukemia Research

Volumn 38, Issue 1, 2014, Pages 84-90

  Holtzer Goor, K M ^a   Bouwmans Frijters, C A M ^a   Schaafsma, M R ^b   de Weerdt, O ^c   Joosten, P ^d   Posthuma, E F M ^e,f   Wittebol, S ^g   Huijgens, P C ^h   Mattijssen, E J M ⁱ   Vreugdenhil, G ^j   Visser, H ^k   Peters, W G ^l   Erjavec, Z ^m   Wijermans, P W ⁿ   Daenen, S M G J ^o   van der Hem, K G ^p   van Oers, M H J ^q   Groot, C A Uyl de ^a  

^a ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^b MEDISCH SPECTRUM TWENTE   (Netherlands)

^c ST ANTONIUS HOSPITAL   (Netherlands)

^d MEDICAL CENTER LEEUWARDEN   (Netherlands)

^e LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^f REINIER DE GRAAF HOSPITAL   (Netherlands)

^g MEANDER MEDICAL CENTER   (Netherlands)

^h VU UNIVERSITY MEDICAL CENTER   (Netherlands)

ⁱ RIJNSTATE HOSPITAL   (Netherlands)

^j MÁXIMA MEDICAL CENTER   (Netherlands)

^k Medical Centre Alkmaar   (Netherlands)

^l CATHARINA HOSPITAL   (Netherlands)

^m Delfzicht Ziekenhuis   (Netherlands)

ⁿ HAGA HOSPITAL   (Netherlands)

^o UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^p ZAANS MEDICAL CENTER   (Netherlands)

^q ACADEMIC MEDICAL CENTER   (Netherlands)

more..

Author keywords

Chronic lymphocytic leukaemia; Cost of illness; Costs; Observational study; Outcomes research; Real world

Indexed keywords

ALEMTUZUMAB; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; FLUDARABINE; RITUXIMAB;

ADULT; ALLOTRANSPLANTATION; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CHRONIC LYMPHATIC LEUKEMIA; CONSULTATION; COST BENEFIT ANALYSIS; DRUG COST; FEMALE; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; NETHERLANDS; OBSERVATIONAL STUDY; PRIORITY JOURNAL;

EID: 84890476752     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2013.10.029     Document Type: Article

References (19)

1. Howlader N., Noone A.M., Krapcho M., Garshell J., Neyman N., Altekruse S.F., et al. SEER Cancer Statistics Review, 1975-2010 2013, National Cancer Institute, Bethesda, MD, http://seer.cancer.gov/csr/1975_2010/, based on November 2012 SEER data submission, posted to the SEER web site, April 2013, [accessed August 2013].
2. Cancer Research UK UK Cancer Incidence (2010) by Country Summary Data 2013, http://publications.cancerresearchuk.org/downloads/Product/CS_DT_INCCOUNTRIES.pdf [accessed August 2013].
3. van den Broek E.C., Kater A.P., van de Schans S.A., Karim-Kos H.E., Janssen-Heijnen M.L., Peters W.G., et al. Chronic lymphocytic leukaemia in the Netherlands: trends in incidence, treatment and survival, 1989-2008. Eur J Cancer 2011, 48(6):889-895.
4. Reis A., Ihle P., Paulus U., Ferber L.V., Diehl V., Walshe R. Cost of illness of malignant lymphoma in Germany. Eur J Cancer Care (Engl) 2006, 15:379-385.
5. Lafeuille M.H., Vekeman F., Wang S.T., Kerrigan M., Menditto L., Duh M.S. Lifetime costs to Medicare of providing care to patients with chronic lymphocytic leukemia. Leuk Lymphoma 2012, 53:1146-1154.
6. Blankart C.R., Koch T., Linder R., Verheyen F., Schreyogg J., Stargardt T. Cost of illness and economic burden of chronic lymphocytic leukemia. Orphanet J Rare Dis 2013, 8(32). 1172-8-32.
7. Lorence D.P., Richards M. Variation in coding influence across the USA. Risk and reward in reimbursement optimization. J Manag Med 2002, 16:422-435.
8. Steinbusch P.J., Oostenbrink J.B., Zuurbier J.J., Schaepkens F.J. The risk of upcoding in casemix systems: a comparative study. Health Policy 2007, 81:289-299.
9. van Agthoven M., Groot M.T., Verdonck L.F., Lowenberg B., Schattenberg A.V., Oudshoorn M., et al. Cost analysis of HLA-identical sibling and voluntary unrelated allogeneic bone marrow and peripheral blood stem cell transplantation in adults with acute myelocytic leukaemia or acute lymphoblastic leukaemia. Bone Marrow Transplant 2002, 30:243-251.
10. Tan S.S., Hakkaart-van Roijen L., Al M.J., Bouwmans C.A., Hoogendoorn M.E., Spronk P.E., et al. A microcosting study of intensive care unit stay in the Netherlands. J Intensive Care Med 2008, 23:250-257.
11. Tan S.S., Van Gils C.W., Franken M.G., Hakkaart-van Roijen L., Uyl-de Groot C.A. The unit costs of inpatient hospital days, outpatient visits, and daycare treatments in the fields of oncology and hematology. Value Health 2010, 13:712-719.
12. Gaultney J.G., Franken M.G., Tan S.S., Redekop W.K., Huijgens P.C., Sonneveld P., et al. Real-world health care costs of relapsed/refractory multiple myeloma during the era of novel cancer agents. J Clin Pharm Ther 2013, 38:41-47.
13. Dutch Healthcare Authority [Nederlandse Zorgautoriteit]. [accessed July 2010]. http://www.nza.nl/.
14. Dutch Healthcare Insurance Board (in Dutch). [accessed July 2010]. http://www.fk.cvz.nl/.
15. Comprehensive Cancer Centre the Netherlands (IKNL). [accessed July 2010]. http://www.cijfersoverkanker.nl/.
16. Kater A.P., van Oers M.H. Chronic lymphocytic leukemia: high time for a risk-adapted approach. Ned Tijdschr Geneeskd 2003, 147:104-109.
17. Blommestein H.M., Verelst S.G., Huijgens P.C., Blijlevens N.M., Cornelissen J.J., Uyl-de Groot C.A. Real-world costs of autologous and allogeneic stem cell transplantations for haematological diseases: a multicentre study. Ann Hematol 2012, 91:1945-1952.
18. Stephens J.M., Gramegna P., Laskin B., Botteman M.F., Pashos C.L. Chronic lymphocytic leukemia: economic burden and quality of life: literature review. Am J Ther 2005, 12:460-466.
19. Kutikova L., Bowman L., Chang S., Long S.R., Arning M., Crown W.H. Medical costs associated with non-Hodgkin's lymphoma in the United States during the first two years of treatment. Leuk Lymphoma 2006, 47:1535-1544.